Focus: LB Pharmaceuticals is a public biotech company focused on schizophrenia treatments, headquartered in New York and founded in 2014. The company operates in the neurology and psychiatry space with a pipeline concentrated on a single lead asset.
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
LB Pharmaceuticals is a high-risk, high-focus play best suited for risk-tolerant professionals seeking deep therapeutic expertise in psychiatry, not for those prioritizing job security or growth opportunities.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for LB Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from LB Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo